Dr. Reddys Labs (RDY) Reports Q4 EPS of $0.49
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Dr. Reddy’s Q4 & FY15 Financial Results
May 12, 2015 7:21 AM EDT
Q4 FY15 Revenues at Rs. 38.7 billion
(YoY growth of 11%)
Q4 FY15 EBITDA at Rs. 8.1 billion
(21% of revenues)
FY15 Revenues at Rs. 148.2 billion
(YoY growth of 12%)
FY15 EBITDA at Rs. 36.2 billion
(24% of revenues)
HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddys Laboratories Ltd. (NYSE: RDY)Â (BSE: 500124)Â (NSE: DRREDDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2015 under International Financial Reporting Standards (IFRS).
FY15: Key... More
